CorMedix to Host April 14 Virtual Fireside Chat at Healthcare Conference
CorMedix management will present at the Needham Virtual Healthcare Conference on April 14 at 3:00pm Eastern with a fireside chat and investor meetings. The webcast will include updates on DefenCath clinical studies and upcoming Q2 2026 topline results for REZZAYO.
1. Conference Participation Details
CorMedix senior management will participate in a fireside chat and one-on-one investor meetings at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 3:00pm Eastern. The session will be webcast live, providing investors direct access to company executives and strategic insights into CorMedix’s development plans.
2. Product Portfolio and Pipeline Updates
CorMedix is commercializing DefenCath for prevention of catheter-related bloodstream infections in hemodialysis patients and a suite of anti-infective products acquired from Melinta Therapeutics. Ongoing clinical studies include DefenCath in Total Parenteral Nutrition and pediatric hemodialysis populations, while REZZAYO’s Phase III prophylaxis study topline results are expected in Q2 2026.